TD Cowen raises target for Exagen stock from USD 10 to USD 11

Published on 10/15/2026 at 13:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Exagen posted USD 19.94 million revenue in the second quarter. Exagen stock trades at EUR 7.50 on October 15, 2026, with results due November 3.

Analyst view and operating scale

TD Cowen lifted its Exagen target from USD 10.00 to USD 11.00 on October 13, 2026.
Second-quarter revenue reached USD 19.94 million, up 16 percent year over year.
Exagen stock traded at EUR 7.50 at 1:29 p.m. CEST at Lang & Schwarz on October 15, 2026.

XGN, US30068X1037, Illustration mit AI erstellt.

Exagen (ISIN US30068X1037) was quoted at EUR 7.50 at Lang & Schwarz on October 15, 2026, at 1:29 p.m. CEST. TD Cowen analyst Dan Brennan raised the price target from USD 10.00 to USD 11.00 on October 13, 2026, according to Markets Insider.

What does the target change signal?

The revised target keeps the analyst view constructive ahead of Exagen's next scheduled report. TD Cowen cited volume growth, margin opportunities and the company's addressable market, while retaining a Buy rating, according to Markets Insider. The target change shifts attention from revenue growth to the path toward sustained profitability.

Three dates define the story

On June 30, 2026, Exagen's second-quarter revenue reached USD 19.94 million, up 16 percent from a year earlier. On August 4, 2026, the company reported adjusted EBITDA loss of USD 0.10 million and raised full-year 2026 revenue guidance to USD 72 million to USD 75 million. On October 13, 2026, TD Cowen lifted its target from USD 10.00 to USD 11.00, as reported by Markets Insider.

Results date and product path

The next earnings report is scheduled for November 3, 2026, according to Earnings Today. Exagen also expects to commercialize its Myositis testing offering in early 2027, according to the company's second-quarter earnings-call transcript carried by Benzinga.

Price and valuation context

Exagen's primary Nasdaq quote was last at USD 8.42 at 4:00 p.m. EDT on October 14, 2026. The company had a market capitalization of USD 204.0 million, while its 52-week range stood at USD 2.59 to USD 12.23.

Exagen stock was trading at EUR 7.50 at Lang & Schwarz on October 15, 2026, at 1:29 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Exagen stock.